zonisamide has been researched along with Seizures in 65 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes." | 9.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting." | 9.13 | Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. ( Conry, JA; Murphy, JV; Vossler, DG, 2008) |
| "To assess the therapeutic efficacy and safety of antiseizure medication (ASM) for a minimum of 6 months, including zonisamide (ZNS), in feline idiopathic epilepsy at a referral hospital in Japan." | 8.31 | Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan. ( Maeda, S; Motegi, T; Yonezawa, T; Yoshida, S, 2023) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 8.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy." | 8.12 | Effectiveness of zonisamide in childhood refractory epilepsy. ( Aslan, M; Gungor, S, 2022) |
| "The present findings revealed that zonisamide treatment prevented the development of seizures in animals." | 7.88 | A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. ( Attri, SV; Kumar, B; Medhi, B; Modi, M; Patial, A; Saikia, B, 2018) |
| "Zonisamide is licensed for adjunctive therapy for partial-onset seizures with or without secondary generalisation in patients 6 years and older and as monotherapy for the treatment of partial seizures in adult patients with newly diagnosed epilepsy, and shows a favourable pharmacokinetic profile with low interaction potential with other drugs." | 7.83 | Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM. ( Baulac, M; Hamer, H; Kockelmann, E; McMurray, R, 2016) |
| "This retrospective study examined the efficacy and safety of zonisamide for Thai children and adolescents with intractable seizures." | 7.81 | Efficacy and safety of zonisamide in Thai children and adolescents with intractable seizures. ( Khongkhatithum, C; Thampratankul, L; Visudtibhan, A, 2015) |
| "Concerning zonisamide (ZNS) therapy, data on sexual dysfunction are not available either in patients with epilepsy or in patients with brain tumor-related epilepsy." | 7.77 | Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. ( Dinapoli, L; Jandolo, B; Maschio, M; Saveriano, F, 2011) |
| " Both the patients developed seizures of various types that have been successfully treated with zonisamide." | 7.74 | Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures. ( Amamiya, S; Araki, A; Fujieda, K; Kajihama, A; Ohinata, J; Sugai, R; Suzuki, N; Takahashi, S; Tanaka, H, 2008) |
| "A 30-year-old woman with primary generalized tonic-clonic seizures and myoclonic jerks was taking zonisamide 200 mg daily as her sole antiepileptic agent when she conceived." | 7.74 | Zonisamide concentrations during pregnancy. ( Bell, WL; Oles, KS, 2008) |
| "We evaluated the anticonvulsive effects of phenobarbital (PB) and zonisamide (ZNS) in the EL mouse, a strain that is highly susceptible to seizures." | 7.69 | Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse. ( Akasaki, Y; Nagase, F; Nagatomo, I; Nomaguchi, M; Takigawa, M, 1996) |
| " Limbic seizure status epilepticus was induced by a unilateral microinjection of kainic acid (KA) into the amygdala." | 7.69 | Zonisamide: electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats. ( Fujita, T; Nakai, H; Takano, K; Tanaka, T; Yonemasu, Y, 1995) |
| "Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods." | 7.30 | Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. ( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023) |
| " Treatment-emergent adverse events (AEs) were reported in 80 patients." | 6.77 | Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. ( Cho, YW; Heo, K; Kim, KS; Kim, OJ; Kim, SE; Kim, SH; Lee, BI; Lee, JH; Lee, SJ; Park, SP; Shin, DJ; Song, HK; Yi, SD, 2012) |
| "A 56-day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers." | 6.69 | Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. ( Buchanan, RA; Kochak, GM; Padgett, CS; Page, JG; Peters, R, 1998) |
| "We examined seizure variables, medical comorbidities, and concomitant medications." | 5.46 | Tolerability of lacosamide or zonisamide in elderly patients with seizures. ( Lee, JW; Nicolas, J; Sarkis, RA, 2017) |
| "Minimal clonic seizures were not suppressed by zonisamide." | 5.36 | Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats. ( Mareš, P, 2010) |
| "During limbic status epilepticus, only seizures in the sensorimotor cortex were markedly attenuated a few minutes after 14C-ZNS administration." | 5.31 | Regional accumulation of 14C-zonisamide in rat brain during kainic acid-induced limbic seizures. ( Akaike, K; Fukumoto, S; Imamura, S; Takigawa, M; Tanaka, S; Tojo, H, 2001) |
| "Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes." | 5.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting." | 5.13 | Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. ( Conry, JA; Murphy, JV; Vossler, DG, 2008) |
| "Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials." | 4.88 | Zonisamide in clinical practice. ( Dupont, S; Stefan, H, 2012) |
| "Based on these data, lacosamide and eslicarbazepine might be more favorable in the treatment of refractory status epilepticus in poststroke epilepsy, when administered as second- or third-line ASMs before anesthesia." | 4.31 | Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study. ( Gonzalez-Escamilla, G; Groppa, S; Sandner, K; Stuckrad-Barre, SV; Vieth, T; Winter, Y, 2023) |
| "To assess the therapeutic efficacy and safety of antiseizure medication (ASM) for a minimum of 6 months, including zonisamide (ZNS), in feline idiopathic epilepsy at a referral hospital in Japan." | 4.31 | Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan. ( Maeda, S; Motegi, T; Yonezawa, T; Yoshida, S, 2023) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 4.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy." | 4.12 | Effectiveness of zonisamide in childhood refractory epilepsy. ( Aslan, M; Gungor, S, 2022) |
| "The present findings revealed that zonisamide treatment prevented the development of seizures in animals." | 3.88 | A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. ( Attri, SV; Kumar, B; Medhi, B; Modi, M; Patial, A; Saikia, B, 2018) |
| " On referral, treatment with levetiracetam, zonisamide, and phenobarbital initially provided good control of cluster seizure activity (attributable to epilepsy of unknow origin)." | 3.85 | Suspected zonisamide-related anticonvulsant hypersensitivity syndrome in a cat. ( Collinet, A; Sammut, V, 2017) |
| "Zonisamide is licensed for adjunctive therapy for partial-onset seizures with or without secondary generalisation in patients 6 years and older and as monotherapy for the treatment of partial seizures in adult patients with newly diagnosed epilepsy, and shows a favourable pharmacokinetic profile with low interaction potential with other drugs." | 3.83 | Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM. ( Baulac, M; Hamer, H; Kockelmann, E; McMurray, R, 2016) |
| "This retrospective study examined the efficacy and safety of zonisamide for Thai children and adolescents with intractable seizures." | 3.81 | Efficacy and safety of zonisamide in Thai children and adolescents with intractable seizures. ( Khongkhatithum, C; Thampratankul, L; Visudtibhan, A, 2015) |
| "In everyday practice, zonisamide is principally used in association with other antiepileptic drugs for the treatment of focal epilepsy in adults." | 3.79 | Management and monitoring of patients treated with zonisamide: the OZONE study. ( Allaf, B; Biraben, A; Dupont, S; Lavernhe, G; Marquet, T, 2013) |
| " However, zonisamide- and carbamazepine-treated animals had IT values similar to those of controls, but only zonisamide significantly decreased absence seizure development." | 3.77 | Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. ( Citraro, R; Constanti, A; De Fazio, S; De Sarro, G; Di Paola, ED; Perrota, I; Perrotta, I; Russo, E; Scicchitano, F, 2011) |
| "Concerning zonisamide (ZNS) therapy, data on sexual dysfunction are not available either in patients with epilepsy or in patients with brain tumor-related epilepsy." | 3.77 | Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. ( Dinapoli, L; Jandolo, B; Maschio, M; Saveriano, F, 2011) |
| " In addition, carbamazepine, zonisamide, and topiramate were more effective in suppressing OB-kindled seizures." | 3.76 | The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics. ( Akagi, M; Fujiwara, A; Ishikawa, T; Kaida, Y; Kamei, C; Takechi, K; Watanabe, Y, 2010) |
| "A 30-year-old woman with primary generalized tonic-clonic seizures and myoclonic jerks was taking zonisamide 200 mg daily as her sole antiepileptic agent when she conceived." | 3.74 | Zonisamide concentrations during pregnancy. ( Bell, WL; Oles, KS, 2008) |
| " Both the patients developed seizures of various types that have been successfully treated with zonisamide." | 3.74 | Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures. ( Amamiya, S; Araki, A; Fujieda, K; Kajihama, A; Ohinata, J; Sugai, R; Suzuki, N; Takahashi, S; Tanaka, H, 2008) |
| "Zonisamide is a broad-spectrum antiepilepsy drug approved in the United States for the adjunctive treatment of partial seizures in adults with epilepsy." | 3.73 | Use of zonisamide in pediatric patients. ( Brotherton, T; Santos, CC, 2005) |
| " Convulsive seizures in the EL mice given the various diets did not differ over 1-4 weeks, but convulsions in EL mice given the Zn-deficient diet for 4 weeks were more effectively suppressed by injection of zonisamide (ZNS) (75 mg/kg intraperitoneally) than in mice receiving high- or adequate-Zn diet for the same period." | 3.70 | Influence of dietary zinc on convulsive seizures and hippocampal NADPH diaphorase-positive neurons in seizure susceptible EL mouse. ( Akasaki, Y; Kuchiiwa, S; Nagatomo, I; Nakagawa, S; Takigawa, M; Uchida, M, 1998) |
| " Limbic seizure status epilepticus was induced by a unilateral microinjection of kainic acid (KA) into the amygdala." | 3.69 | Zonisamide: electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats. ( Fujita, T; Nakai, H; Takano, K; Tanaka, T; Yonemasu, Y, 1995) |
| "We evaluated the anticonvulsive effects of phenobarbital (PB) and zonisamide (ZNS) in the EL mouse, a strain that is highly susceptible to seizures." | 3.69 | Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse. ( Akasaki, Y; Nagase, F; Nagatomo, I; Nomaguchi, M; Takigawa, M, 1996) |
| "Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods." | 3.30 | Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. ( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023) |
| " Treatment-emergent adverse events (AEs) were reported in 80 patients." | 2.77 | Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. ( Cho, YW; Heo, K; Kim, KS; Kim, OJ; Kim, SE; Kim, SH; Lee, BI; Lee, JH; Lee, SJ; Park, SP; Shin, DJ; Song, HK; Yi, SD, 2012) |
| "A 56-day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers." | 2.69 | Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. ( Buchanan, RA; Kochak, GM; Padgett, CS; Page, JG; Peters, R, 1998) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period." | 2.66 | Antiepileptic drugs as prophylaxis for postcraniotomy seizures. ( Dundar, Y; Greenhalgh, J; Marson, AG; Nevitt, SJ; Weston, J, 2020) |
| "Zonisamide is effective against focal seizures in adults and children and, thus, a therapeutic option for such patients." | 2.61 | An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. ( Ljung, H; Reimers, A, 2019) |
| "Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within the first month of cranial surgery." | 2.58 | Antiepileptic drugs as prophylaxis for postcraniotomy seizures. ( Dundar, Y; Greenhalgh, J; Marson, AG; Nevitt, SJ; Weston, J, 2018) |
| "Data regarding antiepileptic drug use in RRT are limited and mostly consist of case reports limiting our proposed dosing recommendations." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure may vary from 3% to 92% over a five-year period." | 2.52 | Antiepileptic drugs as prophylaxis for post-craniotomy seizures. ( Greenhalgh, J; Marson, AG; Weston, J, 2015) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be 15% to 20%; however, the risk of experiencing a seizure may vary from 3% to 92% over a five-year period." | 2.49 | Antiepileptic drugs as prophylaxis for post-craniotomy seizures. ( Greenhalgh, J; Marson, AG; Pulman, J, 2013) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| "Overall, only 24% of the 759 reported seizures had an associated EEG correlate, indicating a high over-reporting rate, which occurred in 57% of patients." | 1.91 | How accurately do adult patients report their absence seizures? ( O'Sullivan, S; Pizarro, J; Walker, MC, 2023) |
| "Under lamotrigine, seizure aggravation was observed in 15 patients (two patients during levetiracetam, one patient during zonisamide, none during phenobarbital and valproic acid)." | 1.62 | Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy. ( Beier, CP; Gesche, J; Hjalgrim, H; Rubboli, G, 2021) |
| "The levetiracetam dosage was increased (150 mg/kg [68 mg/lb], PO, q 8 h), and zonisamide (20 mg/kg [9." | 1.56 | Diagnosis and long-term management of post-traumatic seizures in a white-crowned pionus ( ( Beaufrère, H; Brouwer, E; James, F; Kabakchiev, C; Laniesse, D; Zur Linden, A, 2020) |
| "In five cases, tonic seizures preceded spasms at a median age of 6 weeks." | 1.51 | New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. ( Bienvenu, T; Chikvinidze, G; Dulac, O; Epitashvili, N; Gataullina, S; Melikishvili, G; Tabatadze, N, 2019) |
| "Best seizure control was achieved in patients with poststroke epilepsy; seizure freedom was 80% in this subgroup." | 1.46 | Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers. ( Doğan, EA; Erdoğan, Ç; Genç, BO; Genç, E, 2017) |
| "We examined seizure variables, medical comorbidities, and concomitant medications." | 1.46 | Tolerability of lacosamide or zonisamide in elderly patients with seizures. ( Lee, JW; Nicolas, J; Sarkis, RA, 2017) |
| "Lacosamide decreases seizure burden by modulating sodium channels." | 1.42 | Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: the importance of assessing additional proarrhythmic risks. ( Gudausky, TM; Kovach, J; Loomba, RS; Singh, AK, 2015) |
| "Epileptic myoclonus is generally treated by valproate monotherapy, and this therapy has confirmed efficacy." | 1.38 | Stepwise synchronization through the corpus callosum is one cause of myoclonic jerks. ( Arai, H; Iimura, Y; Nakajima, M; Sugano, H, 2012) |
| "Minimal clonic seizures were not suppressed by zonisamide." | 1.36 | Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats. ( Mareš, P, 2010) |
| " For patients undergoing daytime hemodialysis sessions every 2 or 3 days, the usual dosage of ZNS (4-8 mg/kg/day) may be prescribed once a day in the evening." | 1.32 | Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. ( Fukuda, F; Ijiri, Y; Inoue, T; Kobayashi, T; Shibahara, N; Suzuki, K; Takenaka, H; Tanaka, K, 2004) |
| "During limbic status epilepticus, only seizures in the sensorimotor cortex were markedly attenuated a few minutes after 14C-ZNS administration." | 1.31 | Regional accumulation of 14C-zonisamide in rat brain during kainic acid-induced limbic seizures. ( Akaike, K; Fukumoto, S; Imamura, S; Takigawa, M; Tanaka, S; Tojo, H, 2001) |
| "In the maximal electroshock seizure test, orally at 2 h in mice, 1 had an ED50 of 39 mg/kg." | 1.27 | Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. ( Dodgson, SP; Gardocki, JF; Maryanoff, BE; Nortey, SO; Shank, RP, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.62) | 18.7374 |
| 1990's | 6 (9.23) | 18.2507 |
| 2000's | 17 (26.15) | 29.6817 |
| 2010's | 28 (43.08) | 24.3611 |
| 2020's | 11 (16.92) | 2.80 |
| Authors | Studies |
|---|---|
| Maryanoff, BE | 1 |
| Nortey, SO | 1 |
| Gardocki, JF | 1 |
| Shank, RP | 1 |
| Dodgson, SP | 1 |
| Masereel, B | 1 |
| Rolin, S | 1 |
| Abbate, F | 1 |
| Scozzafava, A | 1 |
| Supuran, CT | 1 |
| Shimshoni, JA | 1 |
| Bialer, M | 1 |
| Yagen, B | 1 |
| Tanaka, T | 2 |
| Yajima, N | 1 |
| Tanitame, A | 1 |
| Kiyoshi, T | 1 |
| Miura, Y | 1 |
| Aslan, M | 1 |
| Gungor, S | 1 |
| Pizarro, J | 1 |
| O'Sullivan, S | 1 |
| Walker, MC | 1 |
| Gristina, BR | 1 |
| Waldron, RJ | 1 |
| Nettifee, JA | 1 |
| Muñana, KR | 1 |
| Yoshida, S | 1 |
| Maeda, S | 1 |
| Yonezawa, T | 1 |
| Motegi, T | 1 |
| Nakatsuka, K | 1 |
| Zanghi, B | 1 |
| Hasegawa, D | 1 |
| Winter, Y | 1 |
| Sandner, K | 1 |
| Vieth, T | 1 |
| Gonzalez-Escamilla, G | 1 |
| Stuckrad-Barre, SV | 1 |
| Groppa, S | 1 |
| Fox, J | 1 |
| Ajinkya, S | 1 |
| Lekoubou, A | 1 |
| Takami, Y | 1 |
| Izawa, T | 1 |
| Tanaka, M | 1 |
| Hatoya, S | 1 |
| Nabetani, T | 1 |
| Yamate, J | 1 |
| Kuwamura, M | 1 |
| Greenhalgh, J | 4 |
| Weston, J | 3 |
| Dundar, Y | 2 |
| Nevitt, SJ | 2 |
| Marson, AG | 4 |
| Kabakchiev, C | 1 |
| Laniesse, D | 1 |
| James, F | 1 |
| Zur Linden, A | 1 |
| Brouwer, E | 1 |
| Beaufrère, H | 1 |
| Gesche, J | 1 |
| Hjalgrim, H | 1 |
| Rubboli, G | 1 |
| Beier, CP | 1 |
| Sarkis, RA | 1 |
| Nicolas, J | 1 |
| Lee, JW | 1 |
| Doğan, EA | 1 |
| Genç, E | 1 |
| Genç, BO | 1 |
| Erdoğan, Ç | 1 |
| Collinet, A | 1 |
| Sammut, V | 1 |
| Kumar, B | 1 |
| Medhi, B | 1 |
| Modi, M | 1 |
| Saikia, B | 1 |
| Attri, SV | 1 |
| Patial, A | 1 |
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 2 |
| Wiencek, JR | 1 |
| Dietzen, DJ | 1 |
| Murray, T | 1 |
| Dawling, S | 1 |
| Colby, JM | 1 |
| Nichols, JH | 1 |
| Park, KM | 1 |
| Lee, BI | 2 |
| Shin, KJ | 1 |
| Ha, SY | 1 |
| Park, J | 1 |
| Kim, SE | 3 |
| Melikishvili, G | 1 |
| Epitashvili, N | 1 |
| Tabatadze, N | 1 |
| Chikvinidze, G | 1 |
| Dulac, O | 1 |
| Bienvenu, T | 1 |
| Gataullina, S | 1 |
| Reimers, A | 1 |
| Ljung, H | 1 |
| Tombini, M | 1 |
| Pellegrino, G | 1 |
| Di Pino, G | 1 |
| Assenza, G | 1 |
| Pulman, J | 1 |
| Nakken, KO | 1 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Dupont, S | 2 |
| Biraben, A | 1 |
| Lavernhe, G | 1 |
| Marquet, T | 1 |
| Allaf, B | 1 |
| Loomba, RS | 1 |
| Singh, AK | 1 |
| Kovach, J | 1 |
| Gudausky, TM | 1 |
| Thampratankul, L | 1 |
| Khongkhatithum, C | 1 |
| Visudtibhan, A | 1 |
| Janszky, J | 1 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Hamer, H | 1 |
| Baulac, M | 1 |
| McMurray, R | 1 |
| Kockelmann, E | 1 |
| Smetana, KS | 1 |
| Cook, AM | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| Oles, KS | 1 |
| Bell, WL | 1 |
| Maschio, M | 1 |
| Saveriano, F | 1 |
| Dinapoli, L | 1 |
| Jandolo, B | 1 |
| Shaikh, AY | 1 |
| Muranjan, MN | 1 |
| Gogtay, NJ | 1 |
| Lahiri, KR | 1 |
| Fujiwara, A | 1 |
| Watanabe, Y | 1 |
| Takechi, K | 1 |
| Ishikawa, T | 1 |
| Kaida, Y | 1 |
| Akagi, M | 1 |
| Kamei, C | 2 |
| Mareš, P | 1 |
| Russo, E | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| De Fazio, S | 1 |
| Perrotta, I | 1 |
| Perrota, I | 1 |
| Di Paola, ED | 1 |
| Constanti, A | 1 |
| De Sarro, G | 1 |
| Iimura, Y | 1 |
| Sugano, H | 1 |
| Nakajima, M | 1 |
| Arai, H | 1 |
| Yi, SD | 1 |
| Cho, YW | 1 |
| Shin, DJ | 1 |
| Song, HK | 2 |
| Kim, OJ | 1 |
| Park, SP | 1 |
| Kim, SH | 1 |
| Lee, JH | 1 |
| Kim, KS | 1 |
| Lee, SJ | 1 |
| Stefan, H | 1 |
| Hashimoto, Y | 1 |
| Araki, H | 1 |
| Futagami, K | 1 |
| Kawasaki, H | 1 |
| Gomita, Y | 1 |
| Ijiri, Y | 1 |
| Inoue, T | 1 |
| Fukuda, F | 1 |
| Suzuki, K | 1 |
| Kobayashi, T | 1 |
| Shibahara, N | 1 |
| Takenaka, H | 1 |
| Tanaka, K | 1 |
| Santos, CC | 1 |
| Brotherton, T | 1 |
| Kwak, SE | 1 |
| Kim, JE | 1 |
| Kim, DS | 1 |
| Won, MH | 1 |
| Choi, HC | 1 |
| Kim, YI | 1 |
| Choi, SY | 1 |
| Kang, TC | 1 |
| Willmore, LJ | 1 |
| Ueda, Y | 1 |
| Doi, T | 1 |
| Tokumaru, J | 1 |
| Nakajima, A | 1 |
| Nagatomo, K | 1 |
| Masumizu, T | 1 |
| Noda, Y | 1 |
| Mori, A | 1 |
| Packer, L | 1 |
| Davenport, RD | 1 |
| Patel, NC | 1 |
| Shinnar, S | 1 |
| Pellock, JM | 1 |
| Conry, JA | 2 |
| Vossler, DG | 1 |
| Murphy, JV | 1 |
| Takahashi, S | 1 |
| Ohinata, J | 1 |
| Suzuki, N | 1 |
| Amamiya, S | 1 |
| Kajihama, A | 1 |
| Sugai, R | 2 |
| Araki, A | 1 |
| Fujieda, K | 1 |
| Tanaka, H | 1 |
| Oka, M | 1 |
| Masuda, Y | 3 |
| Yoshida, K | 2 |
| Shimizu, M | 2 |
| Karasawa, T | 2 |
| Shiraishi, Y | 1 |
| Hori, M | 1 |
| Takano, K | 1 |
| Fujita, T | 1 |
| Nakai, H | 1 |
| Yonemasu, Y | 1 |
| Noguchi, H | 1 |
| Kaneko, S | 1 |
| Okada, M | 1 |
| Hirano, T | 1 |
| Kondo, T | 1 |
| Otani, K | 1 |
| Fukushima, Y | 1 |
| Nagatomo, I | 2 |
| Akasaki, Y | 2 |
| Nagase, F | 1 |
| Nomaguchi, M | 1 |
| Takigawa, M | 3 |
| Kochak, GM | 1 |
| Page, JG | 1 |
| Buchanan, RA | 1 |
| Peters, R | 1 |
| Padgett, CS | 1 |
| Uchida, M | 1 |
| Kuchiiwa, S | 1 |
| Nakagawa, S | 1 |
| Miyamoto, A | 1 |
| Okamoto, T | 1 |
| Shirai, M | 1 |
| Oki, J | 1 |
| Akaike, K | 1 |
| Tanaka, S | 1 |
| Tojo, H | 1 |
| Fukumoto, S | 1 |
| Imamura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for zonisamide and Seizures
| Article | Year |
|---|---|
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2020 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2020 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2018 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2018 |
An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Humans; Se | 2019 |
An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Humans; Se | 2019 |
Antiepileptic drugs as prophylaxis for post-craniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Phenobarbital; Phenytoin; Randomized | 2013 |
Antiepileptic drugs as prophylaxis for post-craniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Phenobarbital; Phenytoin; Randomized | 2013 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
Antiepileptic drugs as prophylaxis for post-craniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Phenobarbital; Phenytoin; Randomized | 2015 |
Antiepileptic drugs as prophylaxis for post-craniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Phenobarbital; Phenytoin; Randomized | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Zonisamide in clinical practice.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Quality of Life; Seizures; Treatment Outco | 2012 |
Zonisamide in clinical practice.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Quality of Life; Seizures; Treatment Outco | 2012 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
5 trials available for zonisamide and Seizures
| Article | Year |
|---|---|
Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study.
Topics: Animals; Diet; Dog Diseases; Dogs; Epilepsy; Prospective Studies; Seizures; Triglycerides; Zonisamid | 2023 |
Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study.
Topics: Animals; Diet; Dog Diseases; Dogs; Epilepsy; Prospective Studies; Seizures; Triglycerides; Zonisamid | 2023 |
Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Partial; Fem | 2012 |
Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Partial; Fem | 2012 |
Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2009 |
Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2009 |
Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Female; Humans; Isoxazoles; Male; Myocl | 2008 |
Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Female; Humans; Isoxazoles; Male; Myocl | 2008 |
Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.
Topics: Anticonvulsants; Half-Life; Humans; Isoxazoles; Metabolic Clearance Rate; Seizures; Zonisamide | 1998 |
Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.
Topics: Anticonvulsants; Half-Life; Humans; Isoxazoles; Metabolic Clearance Rate; Seizures; Zonisamide | 1998 |
50 other studies available for zonisamide and Seizures
| Article | Year |
|---|---|
Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds.
Topics: Animals; Carbonic Anhydrase Inhibitors; Chemical Phenomena; Chemistry; Electroshock; Fructose; Kinet | 1987 |
Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds.
Topics: Animals; Carbonic Anhydrase Inhibitors; Chemical Phenomena; Chemistry; Electroshock; Fructose; Kinet | 1987 |
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
Topics: Acetazolamide; Animals; Anticonvulsants; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhyd | 2002 |
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
Topics: Acetazolamide; Animals; Anticonvulsants; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhyd | 2002 |
Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.
Topics: Administration, Oral; Amides; Animals; Anticonvulsants; Cyclopropanes; Electroshock; Isoxazoles; Mic | 2008 |
Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.
Topics: Administration, Oral; Amides; Animals; Anticonvulsants; Cyclopropanes; Electroshock; Isoxazoles; Mic | 2008 |
Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Effectiveness of zonisamide in childhood refractory epilepsy.
Topics: Child; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Humans; Reproducibility of Results; R | 2022 |
Effectiveness of zonisamide in childhood refractory epilepsy.
Topics: Child; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Humans; Reproducibility of Results; R | 2022 |
How accurately do adult patients report their absence seizures?
Topics: Adult; Epilepsy, Absence; Female; Humans; Inpatients; Male; Seizures; Valproic Acid; Zonisamide | 2023 |
How accurately do adult patients report their absence seizures?
Topics: Adult; Epilepsy, Absence; Female; Humans; Inpatients; Male; Seizures; Valproic Acid; Zonisamide | 2023 |
Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy.
Topics: Animals; Anticonvulsants; Caregivers; Dog Diseases; Dogs; Epilepsy; Humans; Levetiracetam; Phenobarb | 2023 |
Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy.
Topics: Animals; Anticonvulsants; Caregivers; Dog Diseases; Dogs; Epilepsy; Humans; Levetiracetam; Phenobarb | 2023 |
Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan.
Topics: Animals; Cat Diseases; Cats; Epilepsy; Hospitals; Japan; Referral and Consultation; Retrospective St | 2023 |
Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan.
Topics: Animals; Cat Diseases; Cats; Epilepsy; Hospitals; Japan; Referral and Consultation; Retrospective St | 2023 |
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study.
Topics: Aged; Anticonvulsants; Benzodiazepines; Epilepsy; Humans; Ischemic Stroke; Lacosamide; Middle Aged; | 2023 |
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study.
Topics: Aged; Anticonvulsants; Benzodiazepines; Epilepsy; Humans; Ischemic Stroke; Lacosamide; Middle Aged; | 2023 |
Patterns of antiepileptic drug use among elderly patients with epilepsy: 2004-2015.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2020 |
Patterns of antiepileptic drug use among elderly patients with epilepsy: 2004-2015.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2020 |
Hepatocellular necrosis with prominent regenerative reactions in a zonisamide administrated dog.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Liver; Liver R | 2020 |
Hepatocellular necrosis with prominent regenerative reactions in a zonisamide administrated dog.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Liver; Liver R | 2020 |
Diagnosis and long-term management of post-traumatic seizures in a white-crowned pionus (
Topics: Animals; Anticonvulsants; Brain Injuries, Traumatic; Female; Levetiracetam; Parrots; Seizures; Zonis | 2020 |
Diagnosis and long-term management of post-traumatic seizures in a white-crowned pionus (
Topics: Animals; Anticonvulsants; Brain Injuries, Traumatic; Female; Levetiracetam; Parrots; Seizures; Zonis | 2020 |
Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Generalized; Humans; Lamotrigine; Levetiracetam; Myoclonic Epileps | 2021 |
Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Generalized; Humans; Lamotrigine; Levetiracetam; Myoclonic Epileps | 2021 |
Tolerability of lacosamide or zonisamide in elderly patients with seizures.
Topics: Acetamides; Aged; Anticonvulsants; Dizziness; Female; Gait; Humans; Isoxazoles; Lacosamide; Male; Po | 2017 |
Tolerability of lacosamide or zonisamide in elderly patients with seizures.
Topics: Acetamides; Aged; Anticonvulsants; Dizziness; Female; Gait; Humans; Isoxazoles; Lacosamide; Male; Po | 2017 |
Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Tolerance; Epilepsies, Partial; Female; Huma | 2017 |
Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Tolerance; Epilepsies, Partial; Female; Huma | 2017 |
Suspected zonisamide-related anticonvulsant hypersensitivity syndrome in a cat.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Diagnosis, Differential; Drug Hypersensitivity; Epilep | 2017 |
Suspected zonisamide-related anticonvulsant hypersensitivity syndrome in a cat.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Diagnosis, Differential; Drug Hypersensitivity; Epilep | 2017 |
A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Epilepsy; Free Radicals; Inflammatio | 2018 |
A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Epilepsy; Free Radicals; Inflammatio | 2018 |
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
Persistently Increased Alloisoleucine in a Patient with Seizures.
Topics: Anticonvulsants; Blood Chemical Analysis; Child, Preschool; Diagnosis, Differential; Female; Humans; | 2018 |
Persistently Increased Alloisoleucine in a Patient with Seizures.
Topics: Anticonvulsants; Blood Chemical Analysis; Child, Preschool; Diagnosis, Differential; Female; Humans; | 2018 |
Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Middle Aged; Retrospective Studi | 2019 |
Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Middle Aged; Retrospective Studi | 2019 |
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Electro | 2019 |
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Electro | 2019 |
Zonisamide for seizures in Parkinson's disease with dementia.
Topics: Aged; Anticonvulsants; Dementia; Humans; Isoxazoles; Male; Parkinson Disease; Seizures; Zonisamide | 2013 |
Zonisamide for seizures in Parkinson's disease with dementia.
Topics: Aged; Anticonvulsants; Dementia; Humans; Isoxazoles; Male; Parkinson Disease; Seizures; Zonisamide | 2013 |
Management and monitoring of patients treated with zonisamide: the OZONE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Data Collection; Data Interpretation, S | 2013 |
Management and monitoring of patients treated with zonisamide: the OZONE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Data Collection; Data Interpretation, S | 2013 |
Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: the importance of assessing additional proarrhythmic risks.
Topics: Acetamides; Anticonvulsants; Arrhythmias, Cardiac; Child, Preschool; Comorbidity; Humans; Hypoplasti | 2015 |
Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: the importance of assessing additional proarrhythmic risks.
Topics: Acetamides; Anticonvulsants; Arrhythmias, Cardiac; Child, Preschool; Comorbidity; Humans; Hypoplasti | 2015 |
Efficacy and safety of zonisamide in Thai children and adolescents with intractable seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Isoxazoles; Male; Retrospectiv | 2015 |
Efficacy and safety of zonisamide in Thai children and adolescents with intractable seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Isoxazoles; Male; Retrospectiv | 2015 |
Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Drug Toleran | 2016 |
Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Drug Toleran | 2016 |
Zonisamide concentrations during pregnancy.
Topics: Adult; Anticonvulsants; Female; Humans; Isoxazoles; Myoclonic Epilepsy, Juvenile; Pregnancy; Pregnan | 2008 |
Zonisamide concentrations during pregnancy.
Topics: Adult; Anticonvulsants; Female; Humans; Isoxazoles; Myoclonic Epilepsy, Juvenile; Pregnancy; Pregnan | 2008 |
Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on.
Topics: Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Epilepsy; Erectile Dysfunction; Humans; Isoxaz | 2011 |
Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on.
Topics: Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Epilepsy; Erectile Dysfunction; Humans; Isoxaz | 2011 |
Possible mechanism for zonisamide-induced hyperammonemia in a child with citrullinemia type 1.
Topics: Anticonvulsants; Child; Citrullinemia; Humans; Hyperammonemia; Isoxazoles; Male; Seizures; Zonisamid | 2009 |
Possible mechanism for zonisamide-induced hyperammonemia in a child with citrullinemia type 1.
Topics: Anticonvulsants; Child; Citrullinemia; Humans; Hyperammonemia; Isoxazoles; Male; Seizures; Zonisamid | 2009 |
The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Electri | 2010 |
The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Electri | 2010 |
Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Incidence; Isoxazoles; Male; Rat | 2010 |
Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Incidence; Isoxazoles; Male; Rat | 2010 |
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Depression; Dose-Response Relationship, Drug; Electr | 2011 |
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Depression; Dose-Response Relationship, Drug; Electr | 2011 |
Stepwise synchronization through the corpus callosum is one cause of myoclonic jerks.
Topics: Anticonvulsants; Cognition Disorders; Corpus Callosum; Cortical Synchronization; Drug Resistance; El | 2012 |
Stepwise synchronization through the corpus callosum is one cause of myoclonic jerks.
Topics: Anticonvulsants; Cognition Disorders; Corpus Callosum; Cortical Synchronization; Drug Resistance; El | 2012 |
Effects of valproate, phenytoin, and zonisamide on clonic and tonic seizures induced by acute and repeated exposure of mice to flurothyl.
Topics: Animals; Anticonvulsants; Brain Stem; Convulsants; Epilepsy, Tonic-Clonic; Flurothyl; Isoxazoles; Ki | 2003 |
Effects of valproate, phenytoin, and zonisamide on clonic and tonic seizures induced by acute and repeated exposure of mice to flurothyl.
Topics: Animals; Anticonvulsants; Brain Stem; Convulsants; Epilepsy, Tonic-Clonic; Flurothyl; Isoxazoles; Ki | 2003 |
Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis.
Topics: Adult; Anticonvulsants; Anuria; Comorbidity; Drug Administration Schedule; Female; Hemodialysis Solu | 2004 |
Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis.
Topics: Adult; Anticonvulsants; Anuria; Comorbidity; Drug Administration Schedule; Female; Hemodialysis Solu | 2004 |
Use of zonisamide in pediatric patients.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Huma | 2005 |
Use of zonisamide in pediatric patients.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Huma | 2005 |
Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil.
Topics: Animals; Anticonvulsants; Gerbillinae; Hippocampus; In Situ Hybridization; Isoxazoles; Neuropeptide | 2005 |
Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil.
Topics: Animals; Anticonvulsants; Gerbillinae; Hippocampus; In Situ Hybridization; Isoxazoles; Neuropeptide | 2005 |
In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats.
Topics: Animals; Anticonvulsants; Electron Spin Resonance Spectroscopy; Hippocampus; Isoxazoles; Kainic Acid | 2005 |
In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats.
Topics: Animals; Anticonvulsants; Electron Spin Resonance Spectroscopy; Hippocampus; Isoxazoles; Kainic Acid | 2005 |
Electron spin resonance assay of ascorbyl radical generation in mouse hippocampal slices during and after kainate-induced seizures.
Topics: Animals; Anticonvulsants; Ascorbic Acid; Electron Spin Resonance Spectroscopy; Epilepsy, Tonic-Cloni | 2005 |
Electron spin resonance assay of ascorbyl radical generation in mouse hippocampal slices during and after kainate-induced seizures.
Topics: Animals; Anticonvulsants; Ascorbic Acid; Electron Spin Resonance Spectroscopy; Epilepsy, Tonic-Cloni | 2005 |
Zonisamide as treatment for seizures.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Humans; Isoxazoles; Seizures; Zonisamide | 2007 |
Zonisamide as treatment for seizures.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Humans; Isoxazoles; Seizures; Zonisamide | 2007 |
Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures.
Topics: Anticonvulsants; Biological Transport; Child; DNA Mutational Analysis; Erythrocytes; Female; Glucose | 2008 |
Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures.
Topics: Anticonvulsants; Biological Transport; Child; DNA Mutational Analysis; Erythrocytes; Female; Glucose | 2008 |
Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats.
Topics: Amygdala; Animals; Anticonvulsants; Cerebral Cortex; Electric Stimulation; Electroencephalography; H | 1981 |
Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats.
Topics: Amygdala; Animals; Anticonvulsants; Cerebral Cortex; Electric Stimulation; Electroencephalography; H | 1981 |
3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile.
Topics: Animals; Anticonvulsants; Barbiturates; Carbonic Anhydrase Inhibitors; Dogs; Electroshock; Isoxazole | 1980 |
3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile.
Topics: Animals; Anticonvulsants; Barbiturates; Carbonic Anhydrase Inhibitors; Dogs; Electroshock; Isoxazole | 1980 |
Zonisamide: electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats.
Topics: Animals; Anticonvulsants; Autoradiography; Brain; Electroencephalography; Glucose; Isoxazoles; Kaini | 1995 |
Zonisamide: electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats.
Topics: Animals; Anticonvulsants; Autoradiography; Brain; Electroencephalography; Glucose; Isoxazoles; Kaini | 1995 |
Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects.
Topics: Animals; Anticonvulsants; Brain; Carbonic Anhydrase Inhibitors; Electroshock; In Vitro Techniques; I | 1994 |
Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects.
Topics: Animals; Anticonvulsants; Brain; Carbonic Anhydrase Inhibitors; Electroshock; In Vitro Techniques; I | 1994 |
Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread.
Topics: Adenosine; Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Culture Techniques; Dopamine; | 1993 |
Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread.
Topics: Adenosine; Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Culture Techniques; Dopamine; | 1993 |
Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse.
Topics: Animals; Anticonvulsants; Brain Chemistry; Dose-Response Relationship, Drug; Drug Interactions; Fema | 1996 |
Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse.
Topics: Animals; Anticonvulsants; Brain Chemistry; Dose-Response Relationship, Drug; Drug Interactions; Fema | 1996 |
Influence of dietary zinc on convulsive seizures and hippocampal NADPH diaphorase-positive neurons in seizure susceptible EL mouse.
Topics: Animals; Anticonvulsants; Cell Count; Diet; Genetic Predisposition to Disease; Hippocampus; Isoxazol | 1998 |
Influence of dietary zinc on convulsive seizures and hippocampal NADPH diaphorase-positive neurons in seizure susceptible EL mouse.
Topics: Animals; Anticonvulsants; Cell Count; Diet; Genetic Predisposition to Disease; Hippocampus; Isoxazol | 1998 |
Urine stone formation during treatment with zonisamide.
Topics: Anticonvulsants; Child; Encephalitis, Viral; Epstein-Barr Virus Infections; Female; Hematuria; Herpe | 2000 |
Urine stone formation during treatment with zonisamide.
Topics: Anticonvulsants; Child; Encephalitis, Viral; Epstein-Barr Virus Infections; Female; Hematuria; Herpe | 2000 |
Regional accumulation of 14C-zonisamide in rat brain during kainic acid-induced limbic seizures.
Topics: Animals; Anticonvulsants; Carbon Radioisotopes; Excitatory Amino Acid Agonists; Injections, Intraven | 2001 |
Regional accumulation of 14C-zonisamide in rat brain during kainic acid-induced limbic seizures.
Topics: Animals; Anticonvulsants; Carbon Radioisotopes; Excitatory Amino Acid Agonists; Injections, Intraven | 2001 |